Retatrutide
Retatrutide (LY3437943) is Eli Lilly's investigational triple-receptor peptide targeting GLP-1, GIP and glucagon, with up to 24.2% weight loss in Phase 2.
Total Price
฿2800
For research & laboratory use only. Not for human consumption.
Half-Life
6 days
Administration Route
Subcutaneous injection
Triple Receptor Agonist
Targets GLP-1, GIP & glucagon for maximum metabolic effect
24.2% Body Weight Loss
Exceeds semaglutide & tirzepatide in Phase 2 head-to-head
Liver Fat Reduction
Glucagon receptor activation directly drives hepatic lipolysis
Effect Timeline
Appetite suppression kicks in; gastric emptying slows
4–6% weight loss; liver fat begins reducing
Visceral fat visibly reduced; energy expenditure elevated
12–16% weight loss; metabolic rate measurably increased
Start — Week 1–2
Appetite suppression kicks in; gastric emptying slows
Week 4
4–6% weight loss; liver fat begins reducing
Week 8
Visceral fat visibly reduced; energy expenditure elevated
Week 16
12–16% weight loss; metabolic rate measurably increased
Mechanism of Action
Scientific Research
New England Journal of Medicine (2023)
Why Researchers Choose Retatrutide
Retatrutide is the first triple-receptor agonist to reach late-stage metabolic research, and it is studied wherever maximum incretin efficacy matters:
- Tri-receptor pharmacology and additive receptor-engagement studies
- Maximum-efficacy weight-reduction protocols beyond GLP-1 and GLP-1/GIP agonists
- Head-to-head efficacy modelling against semaglutide and tirzepatide
- Energy-expenditure and thermogenesis pathway investigations
- Hepatic lipid metabolism and non-alcoholic steatohepatitis (NASH) research
- Metabolic flexibility and substrate-utilisation studies
How Retatrutide Works
Retatrutide activates three metabolic receptors simultaneously: GLP-1, GIP and glucagon. The GLP-1 and GIP arms work much like tirzepatide, driving glucose-dependent insulin secretion, slowing gastric emptying and suppressing appetite. The addition of glucagon receptor activation is what sets it apart: in the liver, glucagon signalling raises fatty-acid oxidation and lifts basal metabolic rate, so retatrutide acts on energy expenditure as well as energy intake. Because the simultaneous GLP-1 signal offsets glucagon’s glucose-raising effect, the net result in trials was increased calorie burn without harmful blood-sugar elevation, the mechanism behind the up-to-24.2% weight reductions seen in Phase 2.
Retatrutide vs. Semaglutide and Tirzepatide
Retatrutide is a GLP-1, GIP and glucagon triple agonist, one step beyond tirzepatide (dual GLP-1/GIP) and semaglutide (GLP-1 only). The added glucagon axis is why it produced the largest Phase 2 weight loss of the three, though no direct head-to-head trial has been published and Phase 3 studies are ongoing.
Retatrutide Dosing Protocol
Titration: escalate once weekly, roughly every 4 weeks, from 1mg to a 4mg maintenance dose, then up to 8mg or 12mg. The 8mg and 12mg arms produced the greatest weight loss in trials.
Reconstitution and Storage
Reconstitution: use bacteriostatic water (1 to 2ml per vial); swirl gently until fully dissolved, do not shake. After reconstitution: keep refrigerated (2-8°C), use within 28 days, do not freeze, and protect from direct light.
Dosing at a Glance
Route
Subcutaneous injection
Frequency
Once weekly
Typical research dose
0.5–12 mg
Opens the calculator with this peptide preselected. Research reference only.
Product FAQs
Customer Reviews
Excellent product. I have been unable to exercise after a motorbike accident and have still been keeping trim. I can't weigh myself until I go to the gym, but I've had to add another hole to my shorts belt. I now take 2mg a week with no nausea. Painless injections with BAC water, much better than saline, which causes irritation at the injection site.
Crazy good. Taking a moderately low dose of 1mg weekly and have zero desire to eat anything bad for me. Sticking to a 700 calorie deficit with ease. Super fast shipping and great owner too!